Lipid Management CKD Cardiovascular Risk
- Fatty acid metabolism may not be the first issue clinicians associate with chronic kidney disease (CKD), but a growing body of evidence suggests that disordered lipid profiles play...
- A recent narrative review, published in the Korean Journal of Internal Medicine, detailed the complex interplay between fatty acid metabolism and CKD progression.
- Individuals with chronic kidney disease (CKD) are at higher risk of cardiovascular disease (CVD) than the general population, and this risk rises as kidney function declines.2 Dyslipidemia is...
Fatty acid metabolism may not be the first issue clinicians associate with chronic kidney disease (CKD), but a growing body of evidence suggests that disordered lipid profiles play a central role in the cardiovascular risk that shapes long-term outcomes for this population.1
A recent narrative review, published in the
Individuals with chronic kidney disease (CKD) are at higher risk of
The authors conducted the review to address persistent uncertainty about lipid-lowering therapy in CKD, especially in people receiving dialysis or living with kidney transplants. They summarized randomized controlled trials evaluating statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, fibrates, and omega-3 fatty acids, and compared recommendations from major organizations, including Kidney Disease: Improving global Outcomes (KDIGO), the American Heart Association/American College of cardiology, and the European Society of Cardiology.
Across CKD stages 1 through 5 in individuals not receiving dialysis, the evidence consistently supported statin-based therapy for cardiovascular risk reduction. The landmark SHARP trial (
* Attenuation of LDL-C/CVD Link: The observation that the association between LDL-C and cardiovascular risk weakens as kidney function declines is well-established. This is due to factors like altered lipid metabolism and increased inflammation in CKD. National Library of Medicine – LDL-C and CKD
* Evidence Gaps in Advanced CKD: The text correctly points out limited evidence for newer agents in dialysis-dependent CKD and transplant recipients.Research in these areas is ongoing, but definitive recommendations are still evolving. American Society of Nephrology – Lipid Management in CKD
* Reference 1 (Kim JY, Chung SM, Kim NH. 2025): This reference is to a publication dated in the future (2025). As of January 20, 2026, this publication would exist. A search confirms the article exists and was published in the Korean Journal of Internal Medicine. PubMed – Kim JY, Chung SM, Kim NH. 2025
* Reference 2 (Matsushita K, et al. 2010): This is a valid and frequently cited meta-analysis. The Lancet – Matsushita K,et al. 2010
* Reference 3 (Iseki K, et al. 2002): This is a valid and frequently cited study. PubMed – Iseki K, et al. 2002
* Breaking News Check: As of 2026/01/20 04:17:47, there are no major breaking news events substantially altering the landscape of CKD lipid management.Ongoing research continues, but no paradigm shifts have occurred.
PHASE 2: ENTITY-BASED GEO (GENERATIVE ENGINE OPTIMIZATION)
Chronic Kidney Disease (CKD) and Cardiovascular Risk
Table of Contents
Chronic Kidney Disease (CKD) significantly increases the risk of cardiovascular disease (CVD).Managing dyslipidemia – abnormal lipid levels – is a crucial component of mitigating this risk. The Centers for disease Control and Prevention (CDC) estimates that approximately 37 million adults in the United States have CKD.
Lipid Management Strategies in CKD
Current recommendations emphasize individualized treatment approaches. The association between low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk is reduced as kidney function declines, necessitating risk-based strategies rather than strict target-based ones. KDIGO guidelines support this approach.
Role of Statins and Ezetimibe
Statins,with or without ezetimibe,remain the cornerstone of cardiovascular risk reduction for most individuals with CKD not undergoing dialysis. This aligns with recommendations from the American Society of Nephrology (ASN).
Evidence Gaps and Advanced CKD
Significant evidence gaps exist regarding lipid management in advanced stages of CKD, particularly in patients on dialysis and those who have received kidney transplants. Research is ongoing to determine the optimal strategies for these populations. A 2025 review by Kim JY, Chung SM, and Kim NH in the Korean Journal of Internal medicine highlights these critical areas for further inquiry.
Ancient Context and Research
Early research, such as the 2002 study by Iseki K, Y